1. Rapid Flare of Brain Metastases in ALK-Positive Non-Small Cell Lung Cancer after Stopping Crizotinib
- Author
-
Juengsamarn J, Sirachainan E, and Reungwetwattana T
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Crizotinib ,medicine.drug_class ,business.industry ,ALK-Positive ,medicine.disease ,respiratory tract diseases ,ALK inhibitor ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Anaplastic lymphoma kinase ,In patient ,Pediatrics, Perinatology, and Child Health ,Non small cell ,Lung cancer ,business ,medicine.drug - Abstract
The prevalence of Anaplastic lymphoma kinase(ALK) rearrangement in NSCLC is about 7-10%. Currently, there are several ALK inhibitors available in treating this group of patients. Brain metastases occur in approximately 30% of patients with ALK-positive non-small-cell lung cancer (NSCLC), and in patients treated with ALK inhibitor, CNS progression occurs in up to 70% of patients. Patients with brain metastases from ALK-positive NSCLC have a distinct natural history compared with patients with wild-type NSCLC. This article describes the rapid flare of brain metastases in ALK-positive non-small cell lung cancer after stopping Crizotinib.
- Published
- 2017